Overview

Supplemental Benefit of Angiotensin Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate whether an angiotensin II receptor blocker (olmesartan), in addition to conventional treatment, will reduce the mortality and morbidity in hypertensive patients with stable chronic heart failure.
Phase:
Phase 3
Details
Lead Sponsor:
Tohoku University
Treatments:
Angiotensin Receptor Antagonists
Olmesartan
Olmesartan Medoxomil